Financial reports
10-Q
2024 Q3
Quarterly report
7 Nov 24
10-Q
2024 Q2
Quarterly report
7 Aug 24
10-Q
2024 Q1
Quarterly report
7 May 24
ARS
2023 FY
Annual report to shareholders
24 Apr 24
10-K
2023 FY
Annual report
29 Feb 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
Current reports
8-K
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update
7 Nov 24
8-K
Regulation FD Disclosure
11 Sep 24
8-K
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11
7 Aug 24
8-K
Regulation FD Disclosure
10 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
6 Jun 24
8-K
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
7 May 24
8-K
Regulation FD Disclosure
11 Mar 24
8-K
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
29 Feb 24
8-K
Regulation FD Disclosure
26 Feb 24
8-K
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
14 Nov 23
Registration and prospectus
S-3
Shelf registration
31 Aug 23
424B5
Prospectus supplement for primary offering
29 Jun 23
424B3
Prospectus supplement
27 Jun 23
424B5
Prospectus supplement for primary offering
26 Jun 23
424B5
Prospectus supplement for primary offering
11 May 23
S-3
Shelf registration
1 May 23
POS AM
Prospectus update (post-effective amendment)
1 May 23
424B3
Prospectus supplement
28 Mar 23
POS AM
Prospectus update (post-effective amendment)
20 Mar 23
424B3
Prospectus supplement
14 Nov 22
Proxies
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
DEFA14A
Additional proxy soliciting materials
25 Mar 22
DEFA14A
Additional proxy soliciting materials
24 Mar 22
DEFR14A
Revised proxy
4 Mar 22
DEFA14A
Additional proxy soliciting materials
25 Feb 22
DEFM14A
Proxy related to merger
14 Feb 22
PRER14A
Preliminary revised proxy
11 Feb 22
Other
EFFECT
Notice of effectiveness
12 Sep 23
CORRESP
Correspondence with SEC
7 Sep 23
UPLOAD
Letter from SEC
6 Sep 23
EFFECT
Notice of effectiveness
10 May 23
EFFECT
Notice of effectiveness
5 May 23
CORRESP
Correspondence with SEC
5 May 23
UPLOAD
Letter from SEC
4 May 23
EFFECT
Notice of effectiveness
28 Mar 23
EFFECT
Notice of effectiveness
3 Aug 22
CORRESP
Correspondence with SEC
29 Jul 22
Ownership
4
MARK N LAMPERT
8 Oct 24
SC 13D/A
BIOTECHNOLOGY VALUE FUND L P
8 Oct 24
4
Simon Sturge
8 Oct 24
4
MARK N LAMPERT
10 Jun 24
4
Catherine Moukheibir
7 Jun 24
4
Andrew John Phillips
7 Jun 24
4
Ramnik Xavier
7 Jun 24
4
Simon Sturge
7 Jun 24
4
Spike Loy
7 Jun 24
SC 13D/A
BIOTECHNOLOGY VALUE FUND L P
5 Mar 24